Social Media Ideas for Eisai

Japan's Eisai to pump $64m into UK plant to package injectable drugs

<![CDATA[Chai Discovery Enters License Agreement with Pfizer to Accelerate Drug Discovery with AI]]>

‘We think about it every day’: How Daiichi Sankyo’s R&D chief plans to stay ahead in the ADC game

John Tsai, M.D., is rounding out his global drug development resume. Immediately after landing at Daiichi Sankyo, the pharma veteran finds himself leading the R&D portion of th...

Otsuka posts phase 3b ADHD trial win ahead of looming FDA approval decision

A phase 3b trial of Otsuka’s attention-deficit/hyperactivity disorder prospect has hit its primary endpoint, strengthening the drugmaker’s hand weeks before a potential U.S. launch...

<![CDATA[The Origins of Nuvation Bio’s Deal with Daichii Sankyo for the Rights to Safusidenib in Japan]]>

Japan pharma companies turn to China for drug discovery, growth

Samsung Bioepis launches Ustekinumab biosimilar in Japan with Nipro

Samsung Bioepis announced Wednesday the launch of its Ustekinumab biosimilar in Japan, marking the company’s first product debut in the country under a partnership with NIPRO Corp....

<![CDATA[FDA Approves Leqembi Iqlik Subcutaneous Injection for Early Alzheimer’s Disease]]>

Kissei ordered to add warning over vasculitis drug after fatalities

Twenty patients who took Tavneos, a drug for blood vessel inflammation, later died after developing liver dysfunction.

Takeda and Insilico strike AI-led drug discovery deal worth up to $600m

Akeso lung cancer drug shines in trials, boosting hopes in US$20b market

Akeso, whose drug ivonescimab was hailed as biotech’s “DeepSeek moment” amid US competition last year, announced better-than-expected clinical results showing it can treat a type o...

Kailera’s oral GLP-1 asset sees 11% weight loss, hits goals in Chinese phase 3 obesity and diabetes trials

Phase 3 trials of Kailera Therapeutics’ oral GLP-1 prospect have hit their primary endpoints, positioning the biotech’s partner Hengrui Pharma to seek approval in obesity and diabe...

Akeso's Gumokimab (AK111, Anti-IL-17) Approved by NMPA for Moderate-to-Severe Plaque Psoriasis, Bolstering Its Autoimmun...

HONG KONG, June 11, 2026 /PRNewswire/ -- Akeso, Inc. (9926.HK) today announced that the National Medical Products Administration (NMPA) of China has approved gumokimab (AK111), the...

How Daiichi Sankyo aims to become a top five oncology player by 2035

Discover Daiichi Sankyo's pipeline strategy, including how it aims to become a top-five global oncology company by 2035. The post How Daiichi Sankyo aims to become a top five oncol...

Entry Japan with Clarity, Execute with Confidence

For biopharmaceutical companies, Japan is one of the world’s most important markets, but also among the most operationally complex. Many therapies with strong global clinical valid...

‘Not simply saving cost’: Inside Astellas CEO’s 5-year strategy to counter Xtandi’s patent cliff

Staring down a $6 billion patent cliff for its prostate cancer drug Xtandi, Astellas aims to counter the inevitable revenue decline with a 200 billion yen ($1.3 billion) cost-savin...

<![CDATA[Insilico Announces Collaboration with SK Biopharmaceutical for AI-Powered CNS Treatment]]>

Otsuka showcases kidney drug data; Pfizer cuts an AI deal

Voyxact helped preserve kidney function, but left an opening for competing IgAN drugs from Vera and Vertex. Elsewhere, Takeda’s alliance with Innovent paid early dividends and Axso...

Kailera’s three-pronged obesity shot shows promise in early trial

As Lilly completes the pivotal program for its “triple-G” drug, Phase 1 data from Kailera partner Hengrui suggest their offering might spur greater weight loss.

Alkermes’ incoming CEO has a plan to outplay Lilly and Takeda

Blair Jackson says the next 12 months may be the most important in Alkermes’ history, as the brain drugmaker races to join an “orexin” market that analysts see as a multibillion-do...

Akeso, Summit drug extends survival in closely watched lung cancer trial

Ivonescimab reduced the risk of death by one-third compared to chemotherapy in a China-based study that’s seen as an important barometer for a class of cancer immunotherapies known...

<![CDATA[EMA’s CHMP Recommends Eli Lilly’s Jaypirca for Approval]]>

Kailera says obesity pill succeeds in late-stage trial in China

The drug spurred about 10% weight loss over 10 months, though that finding came alongside high rates of gastrointestinal side effects that “alarmed” one analyst.

<![CDATA[FDA Issues CRL to Elevar Therpaeutics for Combination of Rivoceranib and Camrelizumab ]]>